U.K. switches nicotinamide
This article was originally published in The Tan Sheet
Executive Summary
The U.K. health authority approves switching Freederm Gel PL (nicotinamide) acne treatment to OTC. The Medicines and Healthcare products Regulatory Agency Feb. 19 says it reclassified nicotinamide 4 percent topical gel from pharmacy status, similar to nonprescription behind-the-counter in the U.S., to general sale for the treatment of mild to moderate inflammatory acne vulgaris. The change follows Diomed Developments' filing of a switch application (1"The Tan Sheet" Oct, 13, 2008, In Brief)
You may also be interested in...
Nicorette spray among proposed U.K. switches
The U.K. health authority considers applications to switch McNeil Products' Nicorette Nasal Spray smoking-cessation product from pharmacy to general sales status. In addition to the application from the Johnson & Johnson division operating in the U.K., the Medicines and Healthcare products Regulatory Agency seeks comments on P-to-GSL switch applications from Thornton & Rose for Hedrin Lotion (dimecticone) indicated for lice, and from Diomed Developments for Bazuka Treatment Gel (salicylic and lactic acids) for warts, verrucas, corns and calluses, and for Freederm Gel PL (nicotinamide) acne treatment. McNeil Products says since nicotine-replacement therapy patches, gum, lozenges and tablets already are available GSL in the U.K., the spray should be also. The firm says the 0.5 mg per-spray dose of the product is less than the maximum dose allowed for NRT products currently available GSL. Comments on each U.K. application are due by Oct. 29. In the U.S., NRT gum, lozenges and patches are available OTC, but not spray, according to FDA
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.